使用定制三维打印羟基磷灰石-钛颅骨成形植入物进行颅骨重建:美国最大单中心经验
该研究回顾性分析了2019至2022年间18例使用定制三维打印羟基磷灰石-钛植入物行颅骨成形术的患者,中位随访6个月,无植入物相关并发症,所有存活者神经功能有改善,美容效果良好或优秀。作者认为这是美国最大单中心经验,证实了该植入物的既往报告获益。
要点
- 3例(16.6%)出现术后轻微并发症,均与植入物无关,其中1例(5.6%)死亡。
- 所有17例存活者神经功能有某种程度改善,美容效果良好或优秀。
核心结论
- 作者认为其美国最大单中心经验证实了三维打印羟基磷灰石-钛颅骨成形植入物既往报告的获益。
研究设计与样本
- 回顾性研究,从前瞻性维护的数据库中识别2019年至2022年间接受该植入物颅骨成形术的所有患者,回顾病历记录人口学、临床、影像、手术细节、并发症和结局。
- 共纳入18例患者(12男6女),平均年龄39岁(范围20-70岁)。
主要发现
- 去骨瓣减压指征为创伤性脑损伤13例(72.2%)、出血性卒中3例(16.7%)、缺血性卒中2例(11.1%)。
- 颅骨成形术中位时间为140天(范围51-1717天),术前中位改良Rankin量表评分为4分(范围0-5分)。
- 18例患者颅骨成形术均技术成功;3例(16.6%)出现术后轻微并发症,均与植入物无关,包括小实质内血肿1例、轴外血肿1例和癫痫发作1例;这3例中1例(5.6%)于1周后死于疑似肺栓塞。
- 中位随访6个月(范围1-38个月)期间无植入物相关并发症;所有17例存活者均显示某种程度神经功能改善;所有患者美容效果良好或优秀。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although several material options, both natural and synthetic, are available for cranioplasty, the rate of implant-related complications has remained high. A relatively novel, synthetic hydroxyapatite-titanium implant, which combines biocompatibility with biomechanical resilience, has been reported to reduce tissue inflammation, infection, and explantation rates, while delivering superior cosmetic results. However, despite such promising preliminary reports, clinical data supporting its use have remained scarce. METHODS: All the patients who had undergone cranioplasty between 2019 and 2022 using this implant were identified from a prospectively maintained database. Medical records were retrospectively reviewed and the following variables recorded: demographic data, clinical data, radiologic findings, operative details, complications (implant-related and unrelated), and outcomes. RESULTS: A total of 18 patients (12 men and 6 women), with a mean age of 39 years (range, 20-70 years), were identified. The indications for craniectomy were traumatic brain injury (n = 13; 72.2%), hemorrhagic stroke (n = 3; 16.7%), and ischemic stroke (n = 2; 11.1%). The median time to cranioplasty was 140 days (range, 51-1717 days). The median modified Rankin scale score before cranioplasty was 4 (range, 0-5). Cranioplasty was technically successful in all 18 patients. Minor postoperative complications, none related to the implant, were managed conservatively in 3 patients (16.6%), including a small intraparenchymal hematoma in 1, an extra-axial hematoma in 1, and a seizure in 1. Of these 3 patients, 1 (5.6%) died 1 week later of a suspected pulmonary embolism. No implant-related complications occurred after a median follow-up of 6 months (range, 1-38 months). All 17 survivors exhibited some degree of neurologic improvement. The cosmetic result was good or excellent for all patients. CONCLUSIONS: Our experience, the largest in the United States, confirms the previously reported benefits associated with the use of 3-dimensional-printed hydroxyapatite-titanium cranioplasty implants.
引用
- Sorek S, Miller A, Griepp D, et al. Skull Reconstruction Using a Custom-Made, Three-Dimensional-Printed, Hydroxyapatite-Titanium Cranioplasty Implant: Largest Single-Center U.S. Experience. World Neurosurg. 2022. PMID: 36115561. doi:10.1016/j.wneu.2022.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。